With piv­otal da­ta on its Covid-19 an­ti­body in hand, As­traZeneca pre­pares for a mad dash to the FDA

A month af­ter re­veal­ing that its mon­o­clon­al an­ti­body com­bi­na­tion was 77% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19 com­pared to place­bo, As­traZeneca says it’s head­ed to the FDA.

“We’ve cer­tain­ly shared the da­ta with reg­u­la­tors, and we an­tic­i­pate sub­mit­ting the emer­gency use au­tho­riza­tion very short­ly,” Mark Ess­er, VP and head of mi­cro­bial sci­ences and bio­phar­ma­ceu­ti­cals R&D, said dur­ing a press con­fer­ence on Wednes­day af­ter­noon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER